Literature DB >> 15812601

Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.

Hans-Jürgen Möller1.   

Abstract

For a long time,in the context of depressive symptoms in schizophrenia traditional neuroleptics were mostly discussed with respect to possible depressiogenic side effects, although some studies argued that they may also have certain antidepressive effects. However, this was not proven at that time in placebo-controlled studies. Placebo-controlled studies performed in recent years have shown that second generation antipsychotics have antidepressive effects which are significantly stronger than those of the traditional neuroleptics. In addition, it was demonstrated that this antidepressive effect can only partially be explained as being secondary to the improvement of positive and negative symptoms, and is apparently predominantly due to a direct (primary) effect on depressive symptoms. It is of special relevance in this context that the antidepressive effect of second generation antipsychotics was recently demonstrated in depression. The positive results from some studies in bipolar depression are especially impressive and underline the antidepressive potencies of novel antipsychotics beyond the spectrum of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812601     DOI: 10.1007/s00406-005-0580-z

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  79 in total

Review 1.  Suicide and schizophrenia.

Authors:  S G Siris
Journal:  J Psychopharmacol       Date:  2001-06       Impact factor: 4.153

2.  Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression.

Authors:  M O'Connor; H Silver
Journal:  J Clin Psychopharmacol       Date:  1998-02       Impact factor: 3.153

3.  Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study.

Authors:  M Amore; M C Jori
Journal:  Int Clin Psychopharmacol       Date:  2001-11       Impact factor: 1.659

4.  Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.

Authors:  H J Möller; P Boyer; O Fleurot; W Rein
Journal:  Psychopharmacology (Berl)       Date:  1997-08       Impact factor: 4.530

5.  Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.

Authors:  A W Schmidt; L A Lebel; H R Howard; S H Zorn
Journal:  Eur J Pharmacol       Date:  2001-08-17       Impact factor: 4.432

Review 6.  State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics.

Authors:  H J Möller
Journal:  World J Biol Psychiatry       Date:  2000-10       Impact factor: 4.132

7.  A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.

Authors:  H J Möller; H Müller; R L Borison; N R Schooler; G Chouinard
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

8.  Clozapine in the treatment of psychotic refractory depression.

Authors:  D Dassa; A Kaladjian; J M Azorin; S Giudicelli
Journal:  Br J Psychiatry       Date:  1993-12       Impact factor: 9.319

9.  Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.

Authors:  George I Papakostas; Timothy J Petersen; Andrew A Nierenberg; Jessica L Murakami; Jonathan E Alpert; Jerrold F Rosenbaum; Maurizio Fava
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

10.  The range of therapeutic efficacy of atypical antipsychotics: a critical evaluation.

Authors:  Aleksandra Dimova
Journal:  Med Hypotheses       Date:  2003-08       Impact factor: 1.538

View more
  10 in total

Review 1.  Can we really prevent suicide?

Authors:  Maya Schwartz-Lifshitz; Gil Zalsman; Lucas Giner; Maria A Oquendo
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

Review 2.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

Review 3.  Utility of atypical antipsychotics in the treatment of resistant unipolar depression.

Authors:  Charles DeBattista; Jessica Hawkins
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  An unambiguous assay for the cloned human sigma1 receptor reveals high affinity interactions with dopamine D4 receptor selective compounds and a distinct structure-affinity relationship for butyrophenones.

Authors:  Ivan T Lee; Shiuhwei Chen; John A Schetz
Journal:  Eur J Pharmacol       Date:  2007-10-02       Impact factor: 4.432

Review 5.  Systematic of psychiatric disorders between categorical and dimensional approaches: Kraepelin's dichotomy and beyond.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06       Impact factor: 5.270

6.  Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.

Authors:  Hideki Taoka; Takashi Hamamura; Shiro Endo; Shinji Miyata; Kishio Toma; Takeshi Ishihara; Shigetoshi Kuroda
Journal:  Psychopharmacology (Berl)       Date:  2008-09-06       Impact factor: 4.530

7.  Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression.

Authors:  Zoja Babinkostova; Branislav Stefanovski
Journal:  EPMA J       Date:  2011-08-12       Impact factor: 6.543

8.  Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study.

Authors:  A Gabriel
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-12       Impact factor: 2.570

9.  ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.

Authors:  Anna Partyka; Anna Wasik; Magdalena Jastrzębska-Więsek; Paweł Mierzejewski; Przemysław Bieńkowski; Marcin Kołaczkowski; Anna Wesołowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-03-16       Impact factor: 3.000

10.  Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats.

Authors:  Anna Wesołowska; Joanna Rychtyk; Joanna Gdula-Argasińska; Katarzyna Górecka; Natalia Wilczyńska-Zawal; Magdalena Jastrzębska-Więsek; Anna Partyka
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-25       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.